Osteosarcoma, a prevalent primary bone cancer in children,
exhibits
a poor prognosis due to the high prevalence of drug resistance. The
objective of this study was to investigate the potential of fluorescent
ultrafine polyethylenimine-coated caged platinum nanoclusters (PEI-Pt
NCs) as an antitumor agent in osteosarcoma. The primary focus of this
study involved the utilization of osteosarcoma cells (U2-OS and MG-63)
and normal control cells (hBMSC) as the primary subjects of investigation.
The capacity of PEI-Pt NCs to enter osteosarcoma cells was observed
through the implementation of confocal microscopy. The impact of PEI-Pt
NCs on migration and proliferation was assessed through the utilization
of various methodologies, including the CCK8 assay, K
i-67 immunofluorescence, clone formation assay, transwell
assay, and wound healing assay. Furthermore, the influence of PEI-Pt
NCs on apoptosis and its underlying mechanism was explored through
the implementation of flow cytometry and Western blotting techniques.
The PEI-Pt NCs demonstrated the capability to enter osteosarcoma cells,
including the nucleus, while also exhibiting fluorescent labeling
properties. Furthermore, the PEI-Pt NCs effectively impeded the migration
and proliferation of osteosarcoma cells. Additionally, the PEI-Pt
NCs facilitated apoptosis by modulating the BAX-Bcl-2/Caspase 3/PARP
axis. The novel nanomaterial PEI-Pt NCs possess diverse advantageous
capabilities, including the ability to impede cell proliferation and
migration, as well as the capacity to modulate the BAX-Bcl-2/Caspase
3/PARP axis, thereby promoting cell apoptosis. Consequently, this
nanomaterial exhibits promising potential in addressing the issue
of inadequate platinum-based treatment for osteosarcoma.